Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10026396 | 0.87 | ADORA3 (0.61) | LMNATP53ADORA3ADORA2AADORA1 | |
| SCHEMBL10026379 | 0.87 | ADORA3 (0.61) | LMNATP53ADORA3ADORA2AADORA1 | |
| SCHEMBL13084343 | 0.85 | ADORA3 (0.46) | ADORA3ADORA2AADORA1 | |
| SCHEMBL14030794 | 0.81 | EHMT1 (0.43) | TP53ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13084341 | 0.81 | ADORA3 (0.50) | LMNAADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL10026359 | 0.79 | LMNA (0.57) | LMNATP53ADORA3ADORA2AADORA1 | |
| SCHEMBL10026370 | 0.79 | LMNA (0.57) | LMNATP53ADORA3ADORA2AADORA1 | |
| SCHEMBL10026368 | 0.79 | LMNA (0.57) | LMNATP53ADORA3ADORA2AADORA1 | |
| SCHEMBL19366657 | 0.79 | LMNA (0.57) | LMNATP53ADORA3ADORA2AADORA1 | |
| SCHEMBL13046064 | 0.78 | DNMT1 (0.49) | LMNAADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807685-B2 | Therapeutic compounds | CBT DEVELOPMENT LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-20080076776-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076776-A1 | Therapeutic compounds | FPR3, OGFR, OPRK1 | LMNA 3103/4885TP53 4088/4885ADORA3 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.